Lakewood-Amedex Biotherapeutics Inc. (LABT) stock
Close on Nov 11, 2026Market cap $936.03KP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $936.03K
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.22
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Book value per share
- $3.05
- Diluted shares
- 1M
Trading
- Previous close
- $0.42
- Open
- $0.41
- Day's range
- $0.35 – $0.43
- Volume
- 2,731,736
- Average volume (20 days)
- 44,509,981
- RSI (14 days)
- 39.6
- Volatility (1 year)
- 326.1%
- Relative volume
- 0.23×
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | LABT | S&P 500 | Difference | LABT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -49.5% | -2.4% | −47.1 pts | ||
| 3 months | -83.3% | -1.2% | −82.1 pts |
Two years at a glance
Fiscal years 2024 to 2025, USD
Press releases
Releases Lakewood-Amedex Biotherapeutics filed with the SEC as exhibits to Form 8-K or 6-K
Lakewood-Amedex Biotherapeutics stock: common questions
What is Lakewood-Amedex Biotherapeutics's stock price?
LABT closed at $0.40 on Nov 11, 2026, down 5.05% on the day.
What is Lakewood-Amedex Biotherapeutics's market cap?
Lakewood-Amedex Biotherapeutics was worth $936.03K at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
Does Lakewood-Amedex Biotherapeutics pay a dividend?
No. Lakewood-Amedex Biotherapeutics has not paid a cash dividend over the last twelve months.
Who are Lakewood-Amedex Biotherapeutics's competitors?
Companies most similar to Lakewood-Amedex Biotherapeutics by business, industry and size include LLY, JNJ, ABBV, MRK, AZN.
See a number that looks wrong?